0.83 USD
-0.01 (-1.41%)
We assign a fundamental rating of 3 out of 10 to APRE. APRE was compared to 525 industry peers in the Biotechnology industry. While APRE seems to be doing ok healthwise, there are quite some concerns on its profitability. APRE is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- APRE had negative earnings in the past year.
- In the past year APRE has reported a negative cash flow from operations.
- In the past 5 years APRE always reported negative net income.
- APRE had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- APRE's Return On Assets of -91.04% is on the low side compared to the rest of the industry. APRE is outperformed by 72.95% of its industry peers.
- APRE's Return On Equity of -112.02% is in line compared to the rest of the industry. APRE outperforms 42.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -91.04% | ||
| ROE | -112.02% | ||
| ROIC | N/A |
ROA(3y)-163.39%
ROA(5y)-122.63%
ROE(3y)-186.11%
ROE(5y)-140.49%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for APRE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- APRE does not have a ROIC to compare to the WACC, probably because it is not profitable.
- APRE has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, APRE has more shares outstanding
- APRE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- APRE has an Altman-Z score of -34.45. This is a bad value and indicates that APRE is not financially healthy and even has some risk of bankruptcy.
- APRE has a Altman-Z score of -34.45. This is amonst the worse of the industry: APRE underperforms 88.76% of its industry peers.
- There is no outstanding debt for APRE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -34.45 |
ROIC/WACCN/A
WACC8.88%
2.3 Liquidity
- A Current Ratio of 5.20 indicates that APRE has no problem at all paying its short term obligations.
- APRE has a Current ratio (5.20) which is in line with its industry peers.
- A Quick Ratio of 5.20 indicates that APRE has no problem at all paying its short term obligations.
- The Quick ratio of APRE (5.20) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.2 | ||
| Quick Ratio | 5.2 |
3. Growth
3.1 Past
- APRE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.35%, which is quite impressive.
- The Revenue for APRE has decreased by -62.75% in the past year. This is quite bad
EPS 1Y (TTM)40.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.56%
Revenue 1Y (TTM)-62.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-99.44%
3.2 Future
- The Earnings Per Share is expected to grow by 24.45% on average over the next years. This is a very strong growth
- Based on estimates for the next years, APRE will show a very strong growth in Revenue. The Revenue will grow by 144.32% on average per year.
EPS Next Y28.67%
EPS Next 2Y20.18%
EPS Next 3Y19.05%
EPS Next 5Y24.45%
Revenue Next Year-78.54%
Revenue Next 2Y-66.53%
Revenue Next 3Y181.12%
Revenue Next 5Y144.32%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
- APRE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for APRE. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- APRE's earnings are expected to grow with 19.05% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.18%
EPS Next 3Y19.05%
5. Dividend
5.1 Amount
- APRE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
APREA THERAPEUTICS INC / APRE FAQ
Can you provide the ChartMill fundamental rating for APREA THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 3 / 10 to APRE.
What is the valuation status of APREA THERAPEUTICS INC (APRE) stock?
ChartMill assigns a valuation rating of 0 / 10 to APREA THERAPEUTICS INC (APRE). This can be considered as Overvalued.
How profitable is APREA THERAPEUTICS INC (APRE) stock?
APREA THERAPEUTICS INC (APRE) has a profitability rating of 0 / 10.